LUCIUS 卢修斯 厄洛替尼 Erlotinib非小细胞肺癌 胰腺癌

厄洛替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Erlotinib

老挝国家食药监局批准上市
老挝国家药检所检测认证
非小细胞肺癌

Compesiten:
Each film-coated tablet contains Eriotimia hdrochlori
163.9 ma ecunalent to b

LUCiUS

PHARMACEUTICALS

胰腺癌

. The treatment of patients with metastatic non
cEll iuitg cancer (NSCLC) whose tumoes hava asld
prosth lactor receptor (EG eyn o

LuciErlo

ine treatment after progression

onowing at least one priot chan
Fira.rephor chemetheraps resirsen
cht of paticitsy
Dent of patiente with looslle sdun
utresectable or metastatic pancrestie esneor in
comtation with pemcitilns
locally advaace
gemicitabine.

Erlotinib Tablets

FDA批准

NSCLC:150 mg orlly, on an erpty stomnach, one

150mg

*Pancreatic cancer:100 mg oraly, on an empty stomach
ooca duaily.
Storage: in a dry place and stone ut 20°℃ to 25°C
Warning:
Keep medicine oat of reach of Children. Do pot
administer LuciErlo during Pregnancy and Lactation

30 Tablets

PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:
LUCIUS

权威认证

Thongmang village. Xasthany distriet, Vientiane
Capital, Laos
www.lucjus.la

warning : lo be sold by retail on prescriptxon
of registered plysicians onlv, and as directed

Rx Only

口碑质量

适应症:

1、适用于治疗转移性非小细胞肺癌(NSCLC)患者,这些患者的肿
瘤经FDA批准的检测方法发现存在表皮生长因子受体(EGFR)外
显子19缺失或外显子21(L858R)置换突变,且在接受至少一种先

前化疗方案后病情进展,接受一线、维持或二线或更高线治疗。
2、与吉西他滨联合用于局部晚期、不可切除或转移性胰腺癌患者
的一线治疗。
推荐剂量:
NSCLC:每日一次,每次150mg,空腹服用。
胰腺癌:每日一次,每次100mg,空腹服用。